Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

novartis (hellas) a.e.b.e. - estradiol hemihydrate - ΔΙΑΔΕΡΜΙΚΟ ΕΜΠΛΑΣΤΡΟ - 100mcg/24hrs - ineof00486 - estradiol hemihydrate - 0.000000 - estradiol

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

novartis (hellas) a.e.b.e. - estradiol hemihydrate - ΔΙΑΔΕΡΜΙΚΟ ΕΜΠΛΑΣΤΡΟ - 25mcg/24hours - ineof00486 - estradiol hemihydrate - 0.000000 - estradiol

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

proton pharma ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΤΑΙΡΕΙΑ - letrozole - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 2,5mg/tab - 0112809515 - letrozole - 2.500000 mg - letrozole

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

teva pharma b.v., haarlem, the netherlands swensweg5,, 2031 ga haarlem - oxaliplatin - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 5mg/ml - oxaliplatin 5mg - oxaliplatin

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

opus materia ΕΠΕ Παλαιολόγου 33,, 175 64 175 64, Π. Φάληρο 0109408420 - letrozole - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 2,5mg/tab - letrozole 2,5mg - letrozole

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

mylan s.a.s., saint priest, france (0000008105) 117 allee des pares, 69800, saint priest - letrozole - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 2,5mg/tab - 0112809515 letrozole 2.500000 mg - letrozole

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

sandoz gmbh, kundl, austria - letrozole - ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 2,5mg/tab - 0112809515 - letrozole - 2.500000 mg - letrozole

Grecja - grecki - Εθνικός Οργανισμός Φαρμάκων

rafarm a.e.b.e. ΚΟΡΙΝΘΟΥ 12, 15451 Ν. ΨΥΧΙΚΟ 6776550, 6747086 - letrozole - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 2,5mg/tab - letrozole 2,5mg - letrozole

Unia Europejska - grecki - EMA (European Medicines Agency)

accord healthcare s.l.u. - το imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - το imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. Εκτός από τη νεοδιαγνωσθείσα ΧΜΛ σε χρόνια φάση, δεν υπάρχουν ελεγχόμενες μελέτες που να καταδεικνύουν κλινικό όφελος ή αυξημένη επιβίωση για αυτές τις ασθένειες. .

Unia Europejska - grecki - EMA (European Medicines Agency)

actavis group ptc ehf - το imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. Η δράση του imatinib σχετικά με την έκβαση της μεταμόσχευσης μυελού των οστών δεν έχει καθοριστεί. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. Η εμπειρία με imatinib σε ασθενείς με mds/mpd που σχετίζονται με γονιδιακές αναδιατάξεις του pdgfr είναι πολύ περιορισμένη. Δεν υπάρχουν ελεγχόμενες μελέτες που να καταδεικνύουν κλινικό όφελος ή αυξημένη επιβίωση για αυτές τις ασθένειες.